Lung Tissue‐Targeting STING mRNA‐LNPs Inhibits Tumor Progression and Induces Systemic Anti‐Tumor Immunity in Non‐Small Cell Lung Cancer
Small · 2025
DOI: 10.1002/smll.202504715 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2025. Verfasst von Wenhua Tang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou, 213003, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Membrane Proteins, Nanoparticles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province, Major Science and Technology Projects of Changzhou Health Commission.
Abstract (Originalsprache)
The STING pathway holds immunotherapeutic promise but faces challenges in tumor‐specific delivery and systemic toxicity. A lung‐targeting peptide (APWHLSAQYSRT)‐modified lipid nanoparticle (LNP) system (LT‐STING‐LNPs) is developed to deliver STING mRNA for non‐small cell lung cancer (NSCLC) treatment. These spherical, stable LNPs exhibited high mRNA encapsulation efficiency. In vitro, LT‐STING‐LNPs induced potent STING overexpression in lung cells, inhibiting NSCLC cell proliferation, migration, and invasion. In vivo, LNPs demonstrated superior lung tropism, enabling targeted STING activation in pulmonary tissue without systemic distribution. In murine lung metastasis models, treatment drastically reduced metastatic burden, suppressed tumor proliferation (Ki‐67), and inhibited epithelial‐mesenchymal transition (Vimentin). Notably, the platform shows excellent safety with no organ toxicity. LT‐STING‐LNPs synergized robustly with anti‐PD1 therapy, achieving near‐complete metastasis inhibition. Mechanistically, this is driven by STING‐TBK1‐IRF3 signaling activation, inflammatory cytokine (IFN‐α, IL‐1β, CXCL10) production, and immune microenvironment remodeling, including increased CD8+ T cell and M1 macrophage infiltration. This targeted, safe, and highly effective immunotherapy strategy represents a promising advancement for NSCLC, leveraging synergistic STING pathway activation and immune checkpoint blockade.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, The Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou, 213003, China.
- Department of Integrated Chinese and Western Medicine, The Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou, 213003, China.
- Department of Epidemiology and Biostatistics, School of Public Health, Medical College of Soochow University, 199 Renai Road, Suzhou, 215123, China.
ORCID-Profile: Xin Yang
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangsu Province
- Major Science and Technology Projects of Changzhou Health Commission
- Changzhou Science and Technology Project
- Research Project on Emerging Supportive Therapy for Oncology
- Beijing Bethune Charitable Foundation
Zitieren
APA
Tang, W., Xu, X., Hou, H., Zhang, C., Wei, W., Chen, G., Zhang, L., Chen, R., Shen, Y., Ji, M., & Yang, X. (2025). Lung Tissue‐Targeting STING mRNA‐LNPs Inhibits Tumor Progression and Induces Systemic Anti‐Tumor Immunity in Non‐Small Cell Lung Cancer. Small. https://doi.org/10.1002/smll.202504715
Vancouver
Tang W, Xu X, Hou H, Zhang C, Wei W, Chen G, et al. Lung Tissue‐Targeting STING mRNA‐LNPs Inhibits Tumor Progression and Induces Systemic Anti‐Tumor Immunity in Non‐Small Cell Lung Cancer. Small. 2025. doi:10.1002/smll.202504715
BibTeX
@article{Tang2025,
author = {Tang, Wenhua and Xu, Xiaoli and Hou, Hang and Zhang, Chu and Wei, Wei and Chen, Gui and Zhang, Liwen and Chen, Rui and Shen, Yueping and Ji, Mei and Yang, Xin},
title = {Lung Tissue‐Targeting STING mRNA‐LNPs Inhibits Tumor Progression and Induces Systemic Anti‐Tumor Immunity in Non‐Small Cell Lung Cancer},
journal = {Small},
year = {2025},
doi = {10.1002/smll.202504715}
}
EUVIMED